Table 1.

Characteristics of the included studies and outcome events.

Study	NCT number	Study type	Countries	Centers	Publication	Total number of participants	Treatment group	Main outcome events
Mignot et al 2022	NCT03545191	RCT	10	75	Lancet Neurology	930	ACT-541468: 25 mg, 50 mg vs Placebo	a b c d
	NCT03575104	RCT	11	81	Lancet Neurology	924	ACT-541468: 10 mg, 25 mg vs Placebo	a b c d
Dauvilliers et al 2020	NCT02841709	RCT	6	38	ANNALS of Neurology	58	ACT-541468: 5 mg, 10 mg, 25 mg vs Placebo	e f g
Zammit et al 2020	NCT02839200	RCT	2	10	Neurology	360	ACT-541468: 5 mg, 10 mg, 25 mg, 50 mg vs Placebo or 10 mg zolpidem	e f

(a) Change from baseline to month 1 in Wake After Sleep Onset. (b) Change from baseline to month 3 in Wake After Sleep Onset. (c) Change from baseline to month 1 in Latency to Persistent Sleep. (d) Change from baseline to month 3 in Latency to Persistent Sleep. (e) Change in Wake After Sleep Onset from Baseline to days 1 and 2. (f) Change in latency to persistent sleep from baseline to days 1 and 2. (g) Change in subjective wake after sleep onset and subjective latency to sleep onset from baseline recording to week 4 average.